biperiden

Trade name: akineton

Small moleculeapproved

Approved

Sep 8, 1959

Biperiden, sold under the brandname Akineton was used as an adjunct in the therapy of all forms of parkinsonism (postencephalitic, arteriosclerotic and idiopathic). Was also useful in the control of extrapyramidal disorders due to central nervous system drugs such as phenothiazines and other groups of psychotropics. Biperiden is a weak peripheral anticholinergic agent. It has, therefore, some antisecretory, antispasmodic and mydriatic effects. In addition, biperiden possesses nicotinolytic activity. Parkinsonism is thought to result from an imbalance between the excitatory (cholinergic) and inhibitory (dopaminergic) systems in the corpus striatum. The mechanism of action of centrally active anticholinergic drugs such as biperiden is considered to relate to competitive antagonism of acetylcholine at cholinergic receptors in the corpus striatum, which then restores the balance. Atropine-like side effects such as dry mouth; blurred vision; drowsiness; euphoria or disorientation; urinary retention; postural hypotension; constipation; agitation; disturbed behavior may been seen. Only limited pharmacokinetic studies of biperiden in humans are available. — NCATS

Clinical trial activity

7 trials · 10 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
4
Phase 3
5
Phase 4
2

Earliest trial started Jan 1, 2005 (NCT00495092)

Timeline

1950s

  1. Sep 8, 1959

    AbbVie — Earliest FDA Approval

  2. Sep 8, 1959

    AbbVie — NDA Secondary Org

  3. Sep 8, 1959

    AbbVie — NDA Organization

2000s

  1. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedSep 8, 1959

Chemistry & pharmacology

Loading structure…

SMILES

OC(CCN1CCCCC1)(C2CC3CC2C=C3)C4=CC=CC=C4
Mol. weight
311.4611 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral, Parenteral
Availability
Discontinued

Oral

Yes

Parenteral

Yes

Topical

No

Sources

Also known as

  • 1-bicyclo[2.2.1]hept-5-en-2-yl-1-phenyl-3-piperidin-1-yl-propan-1-ol
  • 1-bicyclo[2.2.1]hept-5-en-2-yl-1-phenyl-3-piperidin-1-yl-propan-1-ol
  • akineton
  • akineton
  • akineton
  • akineton
  • akineton
  • akineton ret
  • alpha-5-norbornen-2-yl-alpha-phenyl-1-piperidinepropanol
  • alpha-5-norbornen-2-yl-alpha-phenyl-1-piperidinepropanol
  • alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
  • alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol
  • beperiden
  • beperiden
  • biperiden
  • biperiden
  • biperiden
  • biperiden
  • biperiden
  • biperiden
  • biperiden
  • biperiden
  • biperiden
  • biperiden
  • biperidene
  • biperidene
  • biperidene lactate
  • biperiden hcl
  • biperiden hcl
  • biperiden hcl
  • biperiden hydrochloride
  • biperiden hydrochloride
  • biperiden hydrochloride
  • biperiden hydrochloride
  • biperiden lactate
  • biperiden lactate
  • biperiden lactate
  • biperiden lactate
  • biperiden lactate
  • biperiden lactate
  • biperideno
  • biperideno
  • biperidenum
  • biperidenum

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04945213Phase 3Feb 1, 2022Government of Brazil, Hospital Sirio-Libanes, PROADI-SUS
NCT02374567Phase 3Jan 1, 2015Gottfried Wilhelm Leibniz Universität Hannover
NCT01048138Phase 3Mar 1, 2014Cristália Produtos Químicos Farmacêuticos Ltda., University of Sao Paulo
NCT02078336Phase 4Dec 1, 2013Katholieke Universiteit Leuven
NCT01251393Phase 3May 1, 2011Association for Psychopharmacological Research, Brazil, Nacional Conseling of Scientific Development and Technology, Brazil, University of Sao Paulo
NCT00495183Phase 4Jan 1, 2009Universidad Autonoma de Barcelona
NCT00495092Phase 2/Phase 3 (Phase 3)Jan 1, 2005Universidad Autonoma de Barcelona
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Universidad Autonoma de BarcelonaAcademic/Hospital2222005
University of Sao PauloAcademic/Hospital2212011
Association for Psychopharmacological Research, BrazilAcademic/Hospital1012011
Cristália Produtos Químicos Farmacêuticos Ltda.For profit1012014
Gottfried Wilhelm Leibniz Universität HannoverAcademic/Hospital1112015
Government of BrazilGovernment1012022
Hospital Sirio-LibanesAcademic/Hospital1112022
Katholieke Universiteit LeuvenAcademic/Hospital1112013
Nacional Conseling of Scientific Development and Technology, BrazilAcademic/Hospital1012011
PROADI-SUSAcademic/Hospital1012022
10 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
AbbVieFor profitNDA2Sep 8, 1959
AbbVieFor profitNDASep 8, 1959